Advertisement

Monoclonal antibody therapy

  • Robert O. Dillman
Chapter

Abstract

Antibodies represent one of the first forms of targeted therapy that have been successfully applied to cancer treatment [99]. A chronological history of monoclonal antibody development is shown in Table 1. At the end of the 19th century antisera and antibodies were discovered as part of the independent work of Emil Behring and Kitasato Shibegan in developing diphtheria antitoxin. By immunizing an animal with foreign antigens contained on cells, investigators knew they could produce antisera against an antigen. The German immunologist, bacteriologist, and 1908 Nobel Prize winner Paul Ehrlich used the term ‘passive immunization’ to describe the use of antisera and antibodies in the treatment of disease as opposed to the ‘active immunization’ using cell- or antigen-based vaccines. He is generally recognized as the originator of the term ‘magic bullets’ to describe the potential for antibodies to specifically target bacteria or cancer cells as opposed to normal cells [111]. Thus since the early part of the 20th century it has been theorized that antibodies that react with tumor-associated antigens could be effective reagents for the treatment of malignancy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130: 5–40.PubMedGoogle Scholar
  2. 2.
    Agus DB, Bunn PA Jr, Franklin W et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27 (Suppl. 11): 53–63.PubMedGoogle Scholar
  3. 3.
    Asano M, Yukita A, Matsumoto T et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 185–90.PubMedGoogle Scholar
  4. 4.
    Avner BP, Liao SK, Avner B et al. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Modif 1989; 8: 25–36.Google Scholar
  5. 5.
    Axelrod O, Silverman GJ, Dev V et al. Idiotypic cross-reactivity of immunoglobulins expressed in Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, and mantle %one lymphocytes of secondary B-cell follicles. Blood 1991; 77: 1484–90.PubMedGoogle Scholar
  6. 6.
    Bajorin DF, Chapman PB, Wong G et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50: 7490–5.PubMedGoogle Scholar
  7. 7.
    Ball ED, Bernier GM, Cornwell III GG et al. Monoclonal antibodies to myeloid differentiation antigen: in vivo studies of three patients with acute myelogenous leukemia. Blood 1983; 62: 1203–10.Google Scholar
  8. 8.
    Ball ED, Selvaggi K, Hurd D et al. A phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15. Clin Cancer Res 1995; 1: 965–72.PubMedGoogle Scholar
  9. 9.
    Barker E, Mueller BM, Handgretinger R et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51: 144–9.PubMedGoogle Scholar
  10. 10.
    Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humani%ed anti-p185H ER2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–44.PubMedGoogle Scholar
  11. 11.
    Baselga J, Norton L, Albanell J et al. Recombinant humani%ed anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER/ neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825–31.PubMedGoogle Scholar
  12. 12.
    Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904–14.PubMedGoogle Scholar
  13. 13.
    Bataille R, Barlogie B, Lu ZY et al. Biologic effects of antiinterleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685–91.PubMedGoogle Scholar
  14. 14.
    Beatty JD, Duda RB, Williams LE et al. Preoperative imaging of colorectal carcinoma with 111-In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986; 46: 6494–502.PubMedGoogle Scholar
  15. 15.
    Bergsland E, Hurwit%, Fehrenbacher L et al. A randomi%ed phase II trial comparing rhuMAB VEGF (recombinant humani%ed monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) or FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 2421 (abstract 939).Google Scholar
  16. 16.
    Berinstein NL, Grillo-Lope% AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998: 9: 995–1001.PubMedGoogle Scholar
  17. 17.
    Bertram JH, Gill PS, Levine AM et al. Monoclonal antibody T101 in T-cell malignancies: a clinical, pharmokinetic and immunologic correlation. Blood 1986; 68: 752–61.PubMedGoogle Scholar
  18. 18.
    Bhattacharya-Chatterjee M, Foon KA. Anti-idiotype antibody vaccine therapies of cancer. Cancer Treat Res 1998; 94: 51–68.PubMedGoogle Scholar
  19. 19.
    Blok VT, Daha MR, Tijsma O et al. A bispecific monoclonal antibody directed against both membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160: 3437–43.PubMedGoogle Scholar
  20. 20.
    Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des 2000; 6: 261–76.PubMedGoogle Scholar
  21. 21.
    Borup-Christensen P, Erb K, Jensenius JC et al. Human-human hybridomas for the study of antitumor immune response in patients with colorectal cancer. Int J Cancer 1986; 37: 683–8.PubMedGoogle Scholar
  22. 22.
    Bonner JA, Raisch KP, Trummell HQ et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18 (Suppl.): 47S–53S.PubMedGoogle Scholar
  23. 23.
    Brekken RA, Overholser JP, Stastny VA et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117–24.Google Scholar
  24. 24.
    Brittingham TE, Chaplin H. Production of a human anti-leukemic leukocyte serum and its therapeutic trial. Cancer 1960; 1: 412–18.Google Scholar
  25. 25.
    Brooks D, Tayulor C, Dos Santos B et al. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res 1995; 1: 1259–65.PubMedGoogle Scholar
  26. 26.
    Brown BA, Davis GL, Salt%gaber-Muller J et al. Tumor specific genetically engineered murine/human chimeric monoclonal antibody. Cancer Res 1987; 47: 3577–83.PubMedGoogle Scholar
  27. 27.
    Brown SL, Miller RA, Horning SJ et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651–61.PubMedGoogle Scholar
  28. 28.
    Brown SL, Miller RA, Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16: 199–210.PubMedGoogle Scholar
  29. 29.
    Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936–48.PubMedGoogle Scholar
  30. 30.
    Buchler M, Friess H, Schultheiss K- H et al. A randomi%ed controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991; 68: 1507–12.PubMedGoogle Scholar
  31. 31.
    Buchler P, Reber HA, Buchler MC et al. Therapy for pancreatic cancer with a recombinant humani%ed antiHER2 antibody (Herceptin). J Gastrointest Surg 2001; 5: 139–46.PubMedGoogle Scholar
  32. 32.
    Burdette S, Schwart% RS. Current concepts: immunology. Idiotypes and idiotypic network. N Engl J Med 1987; 317: 219–24.PubMedGoogle Scholar
  33. 33.
    Burnett KG, Masuho Y, Hernande% R et al. Human monoclonal antibodies to breast cancer cells. In: Chatterjee SN, ed. Monoclonal Antibodies, Diagnostic and Therapeutic Use in Tumor and Transplantation. Littleton, MA: PSG Publishing, 1985: 47–62.Google Scholar
  34. 34.
    Burris HA 3rd. Docetaxel (Taxotere) plus trastu%umab (Herceptin) in breast cancer. Semin Oncol 2001; 28 (Suppl. 3): 38–44.PubMedGoogle Scholar
  35. 35.
    Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastu%umab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722–30.PubMedGoogle Scholar
  36. 36.
    Busam KJ, Capodieci P, Mot%er R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169–76.PubMedGoogle Scholar
  37. 37.
    Buter J, Janssen RAJ, Martens A et al. Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer. Eur J Cancer 1993; 29A: 2108–13.Google Scholar
  38. 38.
    Byrd JC, Waselenko JK, Maneatis TA et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side-effects and rapid tumor clearance. J Clin Oncol 1999; 17: 791–5.PubMedGoogle Scholar
  39. 39.
    Byrd JC, Shinn CA, Pearson MD et al. Hu1D10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells independent of complement mediated lysis but requires Fcy receptor ligation. Blood 1999; 94: 314a (abstract 1405).Google Scholar
  40. 40.
    Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–64.PubMedGoogle Scholar
  41. 41.
    Canevari S, Stoter G, Arienti F et al. Regression of advanced ovarian carcinoma by intraperitoneal treatmentGoogle Scholar
  42. with atuologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87: 1463–9.Google Scholar
  43. 42.
    Carrasquillo JA, Bunn PA, Keenan AM et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111-InT101 monoclonal antibody. N Engl J Med 1986; 315: 673–80.PubMedGoogle Scholar
  44. 43.
    Caron PC, Scheinberg DA. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leuk Lymphoma 1993; 11 (Suppl. 2) 1–6.PubMedGoogle Scholar
  45. 44.
    Caron PC, Schwart% MA, Co MS et al. Murine and humani%ed constructs of monoclonal antibody M195 (antiCD33) for the therapy of acute myelogenous leukemia. Cancer 1994; 73: 1049–56.PubMedGoogle Scholar
  46. 45.
    Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humani%ed anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998; 4: 1421–8.PubMedGoogle Scholar
  47. 46.
    Carter PW. Monoclonal antibodies and the biological approach to cancer. J Biol Response Modif 1985; 4: 325–39.Google Scholar
  48. 47.
    Carter P, Presta L, Gorman C et al. Humani%ation of an anti-p185Her2 antibody for human cancer. Proc Natl Acad Sci USA 1992; 89: 4285–9.PubMedGoogle Scholar
  49. 48.
    Casali P, Inghirami G, Nakamura R et al. Human monoclonals from antigen-specific selection of B-lymphocytes and transformation by EBV. Science 1986; 234: 476–8.PubMedGoogle Scholar
  50. 49.
    Caulfield MJ, Murthy S, Tubbs RR et al. Treatment of chronic lymphocytic leukemia with an anti-idiotypic monoclonal antibody. Cleve Clin J Med 1989; 56: 182–8.PubMedGoogle Scholar
  51. 50.
    Caulfield MJ, Barna B, Murthy S et al. Phase Ia/Ib trial of an anti-GD3 monoclonal antibody (R24) in combination with interferon alpha (rHuIFNa-2a) in patients with malignant melanoma. J Biol Response Modif 1990; 9: 319–28.Google Scholar
  52. 51.
    Chachoua A, Orat% R. Liebes L et al. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother 1994; 16: 132–41.Google Scholar
  53. 52.
    Chatterjee SK, Tripathi PK, Chakraborty M et al. Mitchell MS, Oettgen HF, eds. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of anti-idiotype antibody. Cancer Res 1998; 58: 1217–24.Google Scholar
  54. 53.
    Chaudhry A, Carrasquillo JA, Avis IL et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 1999; 5: 3385–93.PubMedGoogle Scholar
  55. 54.
    Chen YH, Shiao RT, Labayog JM et al. Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma. Leuk Lymphoma 1997; 27: 11–23.PubMedGoogle Scholar
  56. 55.
    Cheresh DA, Honsila CJ, Staffileno LK et al. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 1985; 82: 5155–9.PubMedGoogle Scholar
  57. 56.
    Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardi%e response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17: 1244–53.PubMedGoogle Scholar
  58. 57.
    Cheung NK V, La%arus H, Miraldi FD et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430–40.PubMedGoogle Scholar
  59. 58.
    Chiora%%i N, Wasserman RL, Kunkel HG. Use of Epstein-Barr virus-transformed B-cell lines for the generation of immunoglobulin-producing human B-cell hybridomas. J Exp Med 1982; 156: 930–5.Google Scholar
  60. 59.
    Ciardiello F, Bianco R, Damiano V et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909–16.PubMedGoogle Scholar
  61. 60.
    Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humani%ed anti-HER2Google Scholar
  62. monoclonal antibody in women who have HER2-overexperessing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–48.Google Scholar
  63. 61.
    Coiffier B, Haioun C, Ketterer N et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32.PubMedGoogle Scholar
  64. 62.
    Coiffier B, Lepage E, Herbrecht R et al. Mabthera (Rituxan) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomi%ed GELA trial. Blood 2000; 96: 223a (abstract 950).Google Scholar
  65. 63.
    Cole SP, Campling BG, Louwman IH et al. A strategy for the production of human monoclonal antibodies reactive with lung tumor cells. Cancer Res 1984; 44: 2750–3.PubMedGoogle Scholar
  66. 64.
    Colombat P, Salles G, Brousse N et al. Rituximab (antiCD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecualr evaluation. Blood 2001; 97: 101–6.PubMedGoogle Scholar
  67. 65.
    Cote RJ, Morrissey DM, Houghton AN et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA 1983; 80: 2026–30.PubMedGoogle Scholar
  68. 66.
    Courtenay-Luck NS, Epenetos AA, Moore R et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986; 46: 6489–93.PubMedGoogle Scholar
  69. 67.
    Creekmore S, Urba W, Kopp W et al. Phase IB/II trial of R24 antibody and interleukin-2 in melanoma. Proc Am Soc Clin Oncol 1992; 11: 345.Google Scholar
  70. 68.
    Currie GA. Eighty years of immunotherapy: a review of immunobiological methods used in the treatment of cancer. Int J Cancer 1972; 26: 141–53.Google Scholar
  71. 69.
    C%uc%man MS, Grillo-Lope% AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–76.Google Scholar
  72. 70.
    C%uc%man MS, Fallow A, Scarpace A et al. Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma. Blood 2000; 96: 729a (abstract 3154).Google Scholar
  73. 71.
    Davis TA, Maloney DG, Caerwinski DK et al. Antiidiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 1998; 92: 1184–90.PubMedGoogle Scholar
  74. 72.
    Davis T, White CA, Grillo-Lope% A et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–7.PubMedGoogle Scholar
  75. 73.
    Davis TA, C%erwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611–15.PubMedGoogle Scholar
  76. 74.
    Davis TA, Grillo-Lope% AJ, White CA et al. Rituximab antiCD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and eficacy of re-treatment. J Clin Oncol 2000; 18: 3135–43.PubMedGoogle Scholar
  77. 75.
    Davis TA, Maloney DG, Grillo-Lope% AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-a-2a. Clin Cancer Res 2000; 6: 2644–52.PubMedGoogle Scholar
  78. 76.
    Davis TA, Grillo-Lope% AJ, McLaughlin P et al. Is there an optimal time for rituximab retreatment for patients with non-Hodgkin’s lymphoma. Blood 2000; 96: 733a (abstract 3171).Google Scholar
  79. 77.
    Demiden A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC C2B8) monoclonal antibody sensiti%es a B cellGoogle Scholar
  80. lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–86.Google Scholar
  81. 78.
    DePinho RA, Feldman LB, Scharff MD. Tailor-made monoclonal antibodies. Ann Intern Med 1986; 104: 225–33.PubMedGoogle Scholar
  82. 79.
    DeVore RF, Fehrenbacher L, Herbst RS et al. A randomi%ed phase II trial comparing rhumab VEGF (recombinant humani%ed monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19: 485a (abstract 1896).Google Scholar
  83. 80.
    Diamond BA, Yelton DE, Scharff MD. Monoclonal antibodies: a new technology for producing serologic reagents. N Engl J Med 1981; 304: 1344–9.PubMedGoogle Scholar
  84. 81.
    Dillman RO, Shawler DL, Sobol RE et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036–45.PubMedGoogle Scholar
  85. 82.
    Dillman RO, Beauregard JC, Sobol RE et al. Lack of radioimmunodetection and complications associated with monoclonal antibody cross-reactivity with an antigen on circulating cells. Cancer Res 1984; 44: 2213–17.PubMedGoogle Scholar
  86. 83.
    Dillman RO. Monoclonal antibodies in the treatment of cancer. CRC Crit Rev Hematol/Oncol 1984; 1: 357–86.Google Scholar
  87. 84.
    Dillman RO, Shawler DL, Dillman JB et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881–91.PubMedGoogle Scholar
  88. 85.
    Dillman RO, Dillman JB, Halpern SE et al. Toxicities and side effects associated with intravenous infusions of monoclonal antibodies. J Biol Response Modif 1986; 5: 73–84.Google Scholar
  89. 86.
    Dillman RO, Beauregard J, Shawler DL et al. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Response Modif 1986; 5: 394–410.Google Scholar
  90. 87.
    Dillman RO, Johnson DE, Shawler DL. Immune interferon modulation of in vitro murine anti-human T-cell monoclonal antibody mediated cytotoxicity. J Immunol 1986; 136: 728–31.PubMedGoogle Scholar
  91. 88.
    Dillman RO, Shawler DL, Johnson DE, Meyer DL, Ko%iol JA, Frincke JE. Preclinical trials with combinations and conjugates of T101 and doxorubicin. Cancer Res 1986; 46: 4886–91.PubMedGoogle Scholar
  92. 89.
    Dillman RO, Beauregard J, Ryan KP et al. Radioimmunodetection of cancer using indium-labeled monoclonal antibodies. International symposium on labeled and unlabeled antibodies in cancer diagnosis and therapy. NCI Monographs 1987; 3: 33–6.PubMedGoogle Scholar
  93. 90.
    Dillman RO. Antibody therapy. In Oldham RK, ed. Principles of Cancer Biotherapy, 1st edn. New York: Raven Press, 1987: 291–318.Google Scholar
  94. 91.
    Dillman RO, Beauregard JC, Jamieson M et al. Toxicities associated with monoclonal antibody infusions in cancer patients. Mol Biother 1988; 1: 81–5.PubMedGoogle Scholar
  95. 92.
    Dillman RO, Johnson DE, Ogden JR, Beidler D. Significance of antigen, drug and tumor cell targets in the pre-clinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Mol Biother 1989; 1: 250–5.PubMedGoogle Scholar
  96. 93.
    Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989; 111: 592–603.PubMedGoogle Scholar
  97. 94.
    Dillman RO. The human antimouse and antiglobulin responses to monoclonal antibodies. Antibody, Immunocon Radiopharm 1990; 3: 1–15.Google Scholar
  98. 95.
    Dillman RO. Antibody therapy. Iin Oldham RK, ed. Principles of Cancer Biotherapy, 2nd edn. New York: Marcel Dekker, 1991: 395–432.Google Scholar
  99. 96.
    Dillman RO, Shawler DL, McCallister TJ et al. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies. Cancer Biother 1994; 9: 17–28.PubMedGoogle Scholar
  100. 97.
    Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497–515.PubMedGoogle Scholar
  101. 98.
    Dillman RO. Whither magic bullets and guided missiles: monoclonal antibodies 20 years later. Cancer Biother 1995; 10: 177–80.PubMedGoogle Scholar
  102. 99.
    Dillman RO. Magic bullets at last! Finally–approval of a monoclonal antibody for the treatment of cancer!!! Cancer Biother 1997; 12: 223–5.Google Scholar
  103. 100.
    Dillman RO. Antibody therapy. In: Oldham RK, ed. Principles of Cancer Biotherapy, 3rd edn. Dordrecht: Kluwer Academic Publishers, 1998: 284–371.Google Scholar
  104. 101.
    Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18: 465–71.PubMedGoogle Scholar
  105. 102.
    Dillman RO. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm 1999; 14: 5–10.PubMedGoogle Scholar
  106. 103.
    Dillman RO: Monoclonal antibodies for the treatment of lymphoma. Cancer Pract 2001; 9: 71–80.PubMedGoogle Scholar
  107. 104.
    Dimopolous MA, Kiamouris C, Karkantaris C et al. Prospective evaluation of rituximab for the treatment of Waldenstrom’s macroglobulinemia. Blood 2000; 96, 169a (abstract 727).Google Scholar
  108. 105.
    Dorfman NA. The optimal technological approach to the development of human hybridomas. J Biol Response Modif 1985; 4: 213–39.Google Scholar
  109. 106.
    Drapkin R. Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology 2000; 14 (Suppl. 2): 25–9.PubMedGoogle Scholar
  110. 107.
    Dyer MJS, Hale G, Hayhoe FGJ et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–9.PubMedGoogle Scholar
  111. 108.
    Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26 (Suppl. 14): 52–7.PubMedGoogle Scholar
  112. 109.
    Edelson RL, Raafat J, Berger CL, Grossman M, Troyer C, Hardy M. Anti-thymocyte globulin in the management of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63: 675–80.PubMedGoogle Scholar
  113. 110.
    Editorial. Lancet 1994; 344: 1013.Google Scholar
  114. 111.
    Ehrlich P. Uben den jet%igen stand der Kar%inomforschung. In: The Collected Papers of Paul Ehrlich. Vol. II. London: Pergamon Press, 1957: 550–7.Google Scholar
  115. 112.
    Eisenberg BI. The polymerase chain reaction. N Engl J Med 1990; 322: 178–83.Google Scholar
  116. 113.
    Elias DJ, Hirschowit% L, Kline LE et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunoconjugate in patients with non-small cell lung carcinoma. Cancer Res 1990; 50: 4154–9.PubMedGoogle Scholar
  117. 114.
    Ellis JH, Barber KA, Tutt A et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995; 155: 925–37.PubMedGoogle Scholar
  118. 115.
    Emmerich B, Huhn D, Peschel C et al. Treatment of chronic lymphocytic leukemia (CLL) with the anti-CD20 antibody Rituximab. Blood 1999; 94: 309b (abstract 4608).Google Scholar
  119. 116.
    Eumura H, Okajima E, Debruyne FM, Oosterwisk E. Immuni%ation with anti-idiotype monoclonal antibodies bearing the internal image of the renal-cell carcinoma-associated antigen G250 induces specific cellular immune responses. Int J Cancer 1994; 59: 802–7.Google Scholar
  120. 117.
    Ewer MS, Gibbs HR, Swafford J, Benjhamin RS. Cardiotoxicity in patients receiving trastu%umab (Herceptin: primary toxicity, synergistic or sequential stress, or surveillance artifact?) Semin Oncol 1999; 26 (Suppl. 12): 96–101.PubMedGoogle Scholar
  121. 118.
    Fagerberg J, Ragnhammar P, Liljefors M et al. Humoral anti-idiotypic and anti-anti-idiotypic immune response inGoogle Scholar
  122. cancer patients treated with monoclonal antibody 17–1A. Cancer Immunol Immunother 1996; 42: 81–7.Google Scholar
  123. 119.
    Fiddler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217: 998–1003.Google Scholar
  124. 120.
    Fisher RI, Kobota TT, Mandell GL et al. Regression of a T-cell lymphoma after administration of anti-thymocyte globulin. Ann Intern Med 1978; 88: 799–800.PubMedGoogle Scholar
  125. 121.
    Foon KA, Bernhard MI, Oldham RK. Monoclonal antibody therapy: assessment by animal tumor models. J Biol Response Modif 1982; 1: 277–304.Google Scholar
  126. 122.
    Foon KA, Bunn PA, Schroff RW et al. Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: preliminary observations. In: Langman RE, Trowbridge IS, Dulbecco R, eds. Monoclonal Antibody and Cancer. New York: Academic Press, 1984; 39–52.Google Scholar
  127. 123.
    Foon KA, Schroff RW, Bunn PA et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085–93.PubMedGoogle Scholar
  128. 124.
    Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999; 17: 2889–95.PubMedGoogle Scholar
  129. 125.
    Foon KA, Lut%ky J, Baral RN et al. Clinical and immune responses in advanced melanoma patients immuni%ed with an anti-idiotype antibody mimicking disialoganglio side GD2. J Clin Oncol 2000, 18: 376–84.PubMedGoogle Scholar
  130. 126.
    Foran J, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317–24.PubMedGoogle Scholar
  131. 127.
    Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987; 316: 1525–30.PubMedGoogle Scholar
  132. 128.
    Frodin JE, Harmenberg U, Biberfeld P et al. Clinical effects of monoclonal antibodies [MAb 17–1A] in patients with metastatic colorectal carcinomas. Hybridoma 1988; 7: 309–21.PubMedGoogle Scholar
  133. 129.
    Furukawa K, Yamaguchi H, Oettgen HF et al. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. Cancer Res 1989; 49: 191–6.PubMedGoogle Scholar
  134. 130.
    Geha RS. Regulation of the immune response by idiotypeanti-idiotype interactions. N Engl J Med 1981; 305: 25–8.PubMedGoogle Scholar
  135. 131.
    Geha RS. Idiotypic-anti-idiotypic interactions in humans. J Biol Response Modif 1984; 3: 573–9.Google Scholar
  136. 132.
    Gerber HP, Kowalski J, Sherman D et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovasculari%ation requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253–8.PubMedGoogle Scholar
  137. 133.
    Ginaldi L, DeMartinis M, Matutes E et al. Levels of expression of CD 19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364–9.PubMedGoogle Scholar
  138. 134.
    Glassy MC, Handley HH, Hagiwara H et al. UC729–6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc Natl Acad Sci USA 1983; 80: 6327–31.PubMedGoogle Scholar
  139. 135.
    Glassy MC. Immortali%ation of human lymphocytes from a tumor-involved lymph node. Cancer Res 1987; 47: 5181–8.PubMedGoogle Scholar
  140. 136.
    Glassy MC, Dillman RO. Molecular biotherapy with human monoclonal antibodies. Mol Biother 1988; 1: 7–13.PubMedGoogle Scholar
  141. 137.
    Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–8.PubMedGoogle Scholar
  142. 138.
    Gold DV, Alisauskas R, Sharkey RM. Targeting of xeno-grafted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res 1999; 55: 1105–10.Google Scholar
  143. 139.
    Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311–18.PubMedGoogle Scholar
  144. 140.
    Gong MC, Chang SS, Sadelain M et al. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev 1999; 18: 483–90.PubMedGoogle Scholar
  145. 141.
    Goodman GL, Beaumier P, Hellstrom I et al. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3: 340–52.PubMedGoogle Scholar
  146. 142.
    Goodman GE, Hellstrom I, Brod%insky L et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990; 8: 1083–92.PubMedGoogle Scholar
  147. 143.
    Goodman GE, Hellstron I, Yelton DE et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993; 36: 267–73.PubMedGoogle Scholar
  148. 144.
    Gordon MS, Margolin K, Talpa% M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–50.PubMedGoogle Scholar
  149. 145.
    Gottlinger HG, Funke I, Hohnson JP et al. The epithelial cell surface antigen PANOREX, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47–53.PubMedGoogle Scholar
  150. 146.
    Goustin AS, Leof EB, Shipley GD et al. Growth factors and cancer. Cancer Res 1986; 46: 1015–29.PubMedGoogle Scholar
  151. 147.
    Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Meth 1999; 231: 11–23Google Scholar
  152. 148.
    Greene WC, Leonard WJ, Depper JM et al. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T lymphotropic retroviruses. Ann Intern Med 1986; 105: 560–72.PubMedGoogle Scholar
  153. 149.
    Greiner JW, Hand PH, Nugochi P et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 1984; 44: 3208–14.PubMedGoogle Scholar
  154. 150.
    Greiner JW, Guadagni F, Goldstein D et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992; 10: 735–46.PubMedGoogle Scholar
  155. 151.
    Grillo-Lope% AJ, McLaughlin P, Cheson BD et al. First report on the application of the new response criteria proposed for NHL: the rituximab pivotal trial. Proc Am Soc Clin Oncol 1999; 18: 13a (abstract 44).Google Scholar
  156. 152.
    Hainsworth JD, Burris III HA, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052–6.PubMedGoogle Scholar
  157. 153.
    Haisma HJ, Pinedo HM, Kessel MAP et al. Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. J Natl Cancer Inst 1991; 83: 1813–19.PubMedGoogle Scholar
  158. 154.
    Hale G, Dyer M, Clark MR et al. Remission induction in non-Hodgkin’s lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394–9.PubMedGoogle Scholar
  159. 155.
    Halpern SE, Dillman RO, Wit%tum KF et al. Radioimmunodetection of melanoma utili%ing 111-In-96.5 monoclonal antibody: a preliminary report. Radiology 1985; 155: 493–9.PubMedGoogle Scholar
  160. 156.
    Halpern SE, Dillman RO. Radioimmunodetection with monoclonal antibodies against prostatic acid phosphatase.Google Scholar
  161. In: Winkler C, ed. Nuclear Medicine in Clinical Oncology. Berlin: Springer Verlag, 1986: 164–70.Google Scholar
  162. 157.
    Halpern SE, Haindl W, Beauregard J et al. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. Radiology 1988; 168: 529–36.PubMedGoogle Scholar
  163. 158.
    Halpern SE, Dillman RO, Amox D et al. Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies. Arch Surg 1992; 127: 1094–100.PubMedGoogle Scholar
  164. 159.
    Hamblin TJ, Abdul-Ahad AK, Gordon J et al. Preliminary experience in treating lymphocytic leukemia with antibody to immunoglobulin idiotypes on the cell surfaces. Br J Cancer 1980; 42: 495–502.PubMedPubMedCentralGoogle Scholar
  165. 160.
    Hamblin TJ, Cattan AR, Glennie MJ et al. Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood 1987; 69: 790–7.PubMedGoogle Scholar
  166. 161.
    Hartmann F, Renner C, Jung W et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 1998; 91: 2042–7.Google Scholar
  167. 162.
    Haseman MK, Rosenthal SA, Polascik TJ. Capromab pendetide imaging of prostate cancer. Cancer Biother Radiopharm 2000; 15: 131–40.PubMedGoogle Scholar
  168. 163.
    Haspel MV, McCabe RP, Pomato N et al. Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immuni%ed colorectal carcinoma patients. Cancer Res 1985; 45: 3951–61.PubMedGoogle Scholar
  169. 164.
    Hekman A, Honselaar A, Vuist WM et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 1991; 32: 364–72.PubMedGoogle Scholar
  170. 165.
    Hellstrom I, Garrigues U, Lavie E et al. Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Res 1988; 48: 624–7.PubMedGoogle Scholar
  171. 166.
    Henney CS, Gillis S. Cell-mediated cytotoxicity. In: Paul WE, ed. Fundamental Immunology. New York: Raven Press, 1984: 669–84.Google Scholar
  172. 167.
    Heppner GH, Miller BE. Therapeutic implications of tumor heterogeneity. Semin Oncol 1989; 16: 91–105.PubMedGoogle Scholar
  173. 168.
    Herberman RB, Orew ME, Rogentine GN et al. Cytolytic effects of alloantiserum in patients with lymphoproliferative disorders. Cancer 1971; 28: 365–71.PubMedGoogle Scholar
  174. 169.
    Heberman RB, Morgan AC, Reisfeld R et al. Antibody-dependent cellular cytotoxicity (ADCC) against human melanoma by human effector cells in cooperation with mouse monoclonal antibodies. In: Reisfeld RA and Sell S, eds. Monoclonal Antibodies and Cancer Therapy. New York: Liss, 1985: 27: 193–203.Google Scholar
  175. 170.
    Herlyn DM, Steplewski Z, Herlyn MF et al. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40: 717–21.PubMedGoogle Scholar
  176. 171.
    Herlyn D, Koprowski H. IgG2A monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79: 4761–5.PubMedGoogle Scholar
  177. 172.
    Herlyn D, Ross A, Koprowski H. Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986; 232: 100–2.PubMedGoogle Scholar
  178. 173.
    Herlyn D, Wettendorff M, Schmoll E et al. Anti-idiotype immuni%ation of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 1987; 84: 8055–9.PubMedGoogle Scholar
  179. 174.
    Herlyn M, Steplewski Z, Herlyn D et al. CO17–1A and related monoclonal antibodies: their production and characteri%ation. Hybridoma 1986; 5: S3–S10.PubMedGoogle Scholar
  180. 175.
    Hersey P, Schibeci SD, Townsend P et al. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res 1986; 46: 6083–90.PubMedGoogle Scholar
  181. 176.
    Holliger P, Bohlen H. Engineering antibodies for the clinic. Cancer Metastasis Rev 1999; 18: 411–19.PubMedGoogle Scholar
  182. 177.
    Hoogenboom HR, Chames P: Natural and designer binding sites made by phage display technology. Immunol Today 2000; 21: 371–8.PubMedGoogle Scholar
  183. 178.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low grade non-Hodgkin’s lymphoma. N Engl J Med 1984; 311: 1471–5.PubMedGoogle Scholar
  184. 179.
    Houghton AN, Mint%er D, Cordon-Cardo C et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82: 1242–6.PubMedGoogle Scholar
  185. 180.
    Howard O, Gribben J, Neuberg D et al. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. Blood 2000; 96: 63 1 a (abstract 2804 ).Google Scholar
  186. 181.
    Hu F, Epstein AL, Naeve GS et al. A phase Ia clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 1989; 7: 155–66.PubMedGoogle Scholar
  187. 182.
    Hussein MA, Karam MA, McLain DA et al. Biologic and clinical evaluation of rituxan in the management of newly diagnosed multiple myeloma patients. Blood 1999; 94: 313a (abstract 1400).Google Scholar
  188. 183.
    Iliopoulos D, Ernst C, Steplewski Z et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 1989; 81: 440–4.PubMedGoogle Scholar
  189. 184.
    Imai K, Pellegrino MA, Wilson BS et al. Higher cytolytic efficiency of an IgG2A than of an IgG1 monoclonal antibody with the same (or spatially close) determinant on a human molecular-weight melanoma-associated antigen. Cell Immunol 1982; 72: 239–47.PubMedGoogle Scholar
  190. 185.
    Inoue K, Slaton JW, Perrotee P et al. Paclitaxel enhances the effects of the anti-epiermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874–84.PubMedGoogle Scholar
  191. 186.
    Janson D, Hoffman M, Fuchs Aet al. Campath 1-H therapy causes clearing of lymphocytic infiltration of bone marrow in advanced refractory chronic lymphocytic leukemia. Blood 1994; 84 (Suppl. 10): 526a.Google Scholar
  192. 187.
    Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125C: 373.Google Scholar
  193. 188.
    Junghans RP, Waldmann TA, Landolfi NF et al. Anti-tac-H, a humani%ed antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495–502.PubMedGoogle Scholar
  194. 189.
    Jurcic JG, Caron PC, Miller WH Jr et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995; 9: 244–8.PubMedGoogle Scholar
  195. 190.
    Kamigaki T, Yamamoto M, Ohyhanagi H, Saitoh Y. Radiolocali%ation of pancreatic carcinoma xenografts in nude mice with radiolabeled chimeric Fab fragments of anticarcinoembryonic antigen monoclonal antibody A10. Pancreas 1995; 10: 258–64.PubMedGoogle Scholar
  196. 191.
    Kaminski MS, Estes J, Tuck M et al. Iodine I131 tositumomab therapy for previously untreated follicular lymphoma. Proc Am Soc Clin Oncol 2000; 19: 5a (abstract 11).Google Scholar
  197. 192.
    Kan-Mitchell J, Iman A, Kempf RA et al. Human monoclonal antibodies directed against melanoma tumor-associated antigens. Cancer Res 1986; 46: 2490–6.PubMedGoogle Scholar
  198. 193.
    Kat%enwadel A, Schleer H, Gierschner D et al. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res 2000; 20: 1551–5.Google Scholar
  199. 194.
    Keating MJ, Byrd J, Rai K et al. Multicenter study of Campath-1H in patients with chronic lymphoctyc leukemia (B-CLL) refractory to fludarabine. Blood 1999; 94: (Suppl. 1): 705a (abstract 3118).Google Scholar
  200. 195.
    Kelley MJ, Linnoila RI, Avis IL et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997; 112: 256–61.PubMedGoogle Scholar
  201. 196.
    Kennedy RC, Zhou EM, Lanford RE et al. Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest 1987; 80: 1217–24.PubMedPubMedCentralGoogle Scholar
  202. 197.
    Kha%aeli MB, Saleh MN, Liu TP et al. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human y) monoclonal antibody in humans. Cancer Res 1991; 51: 5461–6.Google Scholar
  203. 198.
    Kha%aeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42–52.Google Scholar
  204. 199.
    Khorana A, Bunn P, McLaughlin P et al. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin’s lymphoma. Leuk Lymph 2001; 41: 77–87.Google Scholar
  205. 200.
    Kim YS, Maslinski W, Zheng XX, Schachter AD, Strom TB. Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents. Transplant Proc 1998; 30: 4031–6.PubMedGoogle Scholar
  206. 201.
    Kimby E, Geisler C, Hagbert H et al. Rituximab (Mabthera®) as single agent and in combination with interferon-a-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomi%ed phase II study M 39035. Blood 2000; 96: 577a (abstract 2479).Google Scholar
  207. 202.
    Kiyotaki M, Cooper MD, Bertoli LF et al. Monoclonal anti-Id antibodies react with varying proportions of human B lineage cells. J Immunol 1987; 138: 4150–8.PubMedGoogle Scholar
  208. 203.
    Kirkwood JM, Neumann RD, Zoghbi SS et al. Scintigraphic detection of metastatic melanoma using indium-111 /DTPA conjugated anti-gp240 antibody [ZME018]. J Clin Oncol 1987; 5: 1247–55.PubMedGoogle Scholar
  209. 204.
    Kjeldson TB, Rasmussen BB, Rose C, Zeuthen J. Human-human hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients. Cancer Res 1988; 48: 3208–14.Google Scholar
  210. 205.
    Klein B, Wijdenes J, Zhang XG et al. Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198–204.PubMedGoogle Scholar
  211. 206.
    Knox SJ, Levy R, Hodgkinson S et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991; 77: 20–30.PubMedGoogle Scholar
  212. 207.
    Koda K, Glassy MC, McKnight ME et al. Immunotherapy for recurrent colorelctal cancers with human monoclonal antibody SK-1. Anticancer Res 2001; 21: 621–7.PubMedGoogle Scholar
  213. 208.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predetermined specificity. Nature 1975; 256: 495–597.PubMedGoogle Scholar
  214. 209.
    Kolit% JE, O’Mara KV, Willem%e R et al. Treatment of acute lymphoblastic leukemia with CAMPATH1-H: initial observations. Blood 1994; 84 (Suppl. 11): 301a.Google Scholar
  215. 210.
    Koprowski H, Steplewski Z, Herlyn D et al. Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 1978; 75: 3405–9.PubMedGoogle Scholar
  216. 211.
    Koprowski H, Herlyn D, Lubeck M et al. Human antiidiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 1984; 81: 216–19.PubMedGoogle Scholar
  217. 212.
    Kosmos C, Epenetos AE, Colurtenay-Luck NS. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 1994; 73: 3000–10.Google Scholar
  218. 213.
    Kossman SE, Scheinberg DA, Jurcic JG et al. A phase I trial of humani%ed monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin-2 in acute myelogenous leukemia. Clin Cancer Res 1999; 5: 2748–55.PubMedGoogle Scholar
  219. 214.
    Kranenborg MH, Boerman OC, de Weijert MC et al. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997; 80: 2390–7.PubMedGoogle Scholar
  220. 215.
    Larrick JW, Bourla JM. Prospects for therapeutic use of human monoclonal antibodies. J Biol Response Modif 1986; 5: 379–93.Google Scholar
  221. 216.
    Larson SM, Brown, JP, Wright PW et al. Imaging of melanoma with I-131-labeled monoclonal antibodies. J Nucl Med 1982; 24: 123–9.Google Scholar
  222. 217.
    Las%lo J, Buckley CE, Amos DB. Infusion of isologous immune plasma in chronic lymphocytic leukemia. Blood 1968; 31: 104–10.Google Scholar
  223. 218.
    Lauria F, Lenoci M, Annino L et al. Efficacy of Mabthera (anti-CD20 Ab) in patients with relapsed/progressed hairy cell leukemia. Blood 2000; 96: 138a (abstract 592).Google Scholar
  224. 219.
    Leder P. The genetics of antibody diversity. Sci Am 1980; 243: 102–15.Google Scholar
  225. 220.
    Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565–70.PubMedGoogle Scholar
  226. 221.
    Lee KS. Requirement for neuroregulin receptor, erbB2, in neural and cardiac development. Nature 1995; 379: 394–6.Google Scholar
  227. 222.
    Leonard JP, Coleman M, Schuster MW et al. Immunotherapy of NHL with Epratu%umab (anti-CD22) monoclonal antibody: excellent tolerability with objective responses. Proc Am Soc Clin Oncol 2000; 19: 17a (abstract 60).Google Scholar
  228. 223.
    Leonard JP, Coleman M, Chadburn A et al. Epratu%umab (HLI.2, anti-Cd22 humani%ed monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell, non-Hodgkin’s lymphoma. Blood 2000; 96: 578a (abstract 2482).Google Scholar
  229. 224.
    Leroy M. Teillac P, Rain JD et al. Radioimmunodetection of lymph node invasion in prostatic cancer. Cancer 1989; 64: 1–5.PubMedGoogle Scholar
  230. 225.
    Levy R, Miller RA. Biological and clinical indications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annu Rev Med 1983; 34: 107–16.PubMedGoogle Scholar
  231. 226.
    Levy R. Will monoclonal antibodies find a place in our therapeutic armamentarium? J Clin Oncol 1987; 5: 527–9.PubMedGoogle Scholar
  232. 227.
    Liao S, Kwong PC, Khosravi M, Dent PB. Enhanced expression of melanoma-associated antigens and B2-microglobulin on cultured human melanoma cells by interferon. J Natl Cancer Inst 1982; 68: 19–25.PubMedGoogle Scholar
  233. 228.
    Liao SK, Meranda C, Avner BP et al. Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies. Cancer Immunol Immunother 1989; 28: 77–86.PubMedGoogle Scholar
  234. 229.
    Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1962–3.PubMedGoogle Scholar
  235. 230.
    Lindstrom BA. An experimental study of myelotoxic sera. Therapeutic attempts in myeloid leukaemia. Acta Med Scand Suppl 1927; 22: 1769–75.Google Scholar
  236. 231.
    Liu AY, Robinson RR, Hellstrom AE et al. Chimericmouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987; 84: 3439–43.PubMedGoogle Scholar
  237. 232.
    Liu AY, Robinson RR, Murray Ed et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987; 139: 3521–6.PubMedGoogle Scholar
  238. 233.
    LoBuglio AF, Saleh MN, Lee J et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17–1A. I. Clinic aspects. J Natl Cancer Inst 1988; 17: 932–6.Google Scholar
  239. 234.
    LoBuglio AF, Wheeler RH, Trang J et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4.PubMedGoogle Scholar
  240. 235.
    Lowder JN, Meeker TC, Campbell M et al. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood 1987; 69: 199–210.PubMedGoogle Scholar
  241. 236.
    Lubeck MD, Steplewski Z, Baglia F et al. The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol 1985; 135: 1299–304.PubMedGoogle Scholar
  242. 237.
    Lucas JB, Hoppe RT, Horwit% SM et al. Rituximab is active in lymphocyte predominance Hodgkin’s disease. Blood 2000; 96: 831a (abstract 3592).Google Scholar
  243. 238.
    Luiten RM, Coneyh LR, Fleuren GJ et al. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 1996; 74: 735–44.PubMedPubMedCentralGoogle Scholar
  244. 239.
    Lundin J, Osterborg A, Brittinger G et al. CAMPATH1-H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. J Clin Oncol 1998; 16: 3257–63.PubMedGoogle Scholar
  245. 240.
    Mach J-P, Chatal J-F, Lumbroso J-D et al. Tumor locali%ation in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 1983; 43: 5593–600.PubMedGoogle Scholar
  246. 241.
    Maguire RT, VanNostrand D. Diagnosis of Colorectal and Ovarian Carcinoma. New York: Marcel Dekker, 1992.Google Scholar
  247. 242.
    Maloney DG, Donovan K, Hamblin TJ. Antibody therapy for treatment of multiple myeloma. Semin Hematol 1999; 36 (Suppl. 3): 30–3.PubMedGoogle Scholar
  248. 243.
    Maloney DG, Levy R, Miller RA. Monoclonal antiidiotype therapy of B cell lymphoma. Biol Ther Cancer Updates 1992; 6: 1–10.Google Scholar
  249. 244.
    Maloney DG, Liles TM, C%erwinski DK et al. Phase I clinical trial using escalating single dose infusion of chimeric monoclonal antibody (IDEC C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–66PubMedGoogle Scholar
  250. 245.
    Maloney DG, Grillo-Lope% AJ, Bodkin DJ et al. IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 3266–74.PubMedGoogle Scholar
  251. 246.
    Maloney DG, Grillo-Lope% AJ, Whikte CA et al. IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188–95.PubMedGoogle Scholar
  252. 247.
    Manshouri T, Saffer H, Keating, Albitar M. Clinical relevance of circuating CD20 in patients with chronic lymphocytic leukemia. Blood 2000; 96: 369a (abstract 1595).Google Scholar
  253. 248.
    Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humani%ed monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851–6.PubMedGoogle Scholar
  254. 249.
    Mass RD, Sanders C, Charlene K et al. The concordance between the clinical trials assay and fluorescence in situ hybridi%ation (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 2000; 19: 75a (abstract 291).Google Scholar
  255. 250.
    Masui H, Kawamoto T, Sato JD et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002–7.PubMedGoogle Scholar
  256. 251.
    Mathas S, Rickers A, Bommert K et al. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000; 60: 7170–6.PubMedGoogle Scholar
  257. 252.
    Meeker TC, Lowder J, Maloney DG et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349–72.PubMedGoogle Scholar
  258. 253.
    Meeker T, Lowder J, Cleary ML et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. Blood 1985; 65: 1373–81.Google Scholar
  259. 254.
    Mellstedt H, Frodin J-E, Masucci G et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991; 18: 462–77.PubMedGoogle Scholar
  260. 255.
    Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 2000; 6: 747–53.PubMedGoogle Scholar
  261. 256.
    Met%ger H, Kinnet JP. How antibodies work: focus on Fc receptors. FASEB J 1988; 2: 311.Google Scholar
  262. 257.
    McLaughlin P, Grillo-Lope% AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33.PubMedGoogle Scholar
  263. 258.
    Miller RA, Maloney DG, Warnke R et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1981; 306: 517–22.Google Scholar
  264. 259.
    Miller RA, Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 1981; 2: 226–30.PubMedGoogle Scholar
  265. 260.
    Miller RA, Maloney DG, McKillop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981; 58: 78–86.PubMedGoogle Scholar
  266. 261.
    Miller RA, Oseroff AR, Stratte PT et al. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983; 62: 988–95PubMedGoogle Scholar
  267. 262.
    Miller RA, Hart S, Samos%uk M et al. Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med 1989; 321: 851–7.PubMedGoogle Scholar
  268. 263.
    Minasian LM, S%atrowski TP, Rosenblum M et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-a and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 1994; 83: 56–64.PubMedGoogle Scholar
  269. 264.
    Minasian ML, Yao TJ, Steffens TA et al. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor inpatients with metastatic melanoma. Cancer 1995; 75: 2251–7.Google Scholar
  270. 265.
    Mittelman A, Chen ZJ, Kageshita T et al. Active specific immunotherapy in patients with melanoma: a clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990; 86: 2136–44.PubMedPubMedCentralGoogle Scholar
  271. 266.
    Mittelman A, Chen ZJ, Yang H et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992; 89: 466–70.PubMedGoogle Scholar
  272. 267.
    Modjtahedi H, Hickish T, Nicolson Metal. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 228–35.PubMedPubMedCentralGoogle Scholar
  273. 268.
    Molodofsky PJ, Sears HF, Mulhearn Jr CB et al. Detection of metastatic tumor in normal si%ed retroperitoneal lymph nodes by monoclonal antibody imaging. N Engl J Med 1984; 311: 106–7.Google Scholar
  274. 269.
    Molthoff CF, Prinssen HM, Kenemans P et al. Escalating protein doses of chimeric monoclonal antibody Mov18 immunoglobulin G in ovarian carcinoma patients: a phaseGoogle Scholar
  275. I study. Cancer 1997; 80: 2712–20.Google Scholar
  276. 270.
    Moreau P, Harousseau JL, Wijdenes J et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. BrGoogle Scholar
  277. J Haematol 2000; 109: 661–4.Google Scholar
  278. 271.
    Morgan AC Jr, Sullivan W, Graves S, Woodhouse CS. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-Google Scholar
  279. mediated cytotoxicity by interleukin 2. Cancer Res 1989; 49: 2773–6.Google Scholar
  280. 272.
    Morrison SL, Oi T. Genetically engineered antibody molecules. Adv Immunol 1989; 44: 65–92.PubMedGoogle Scholar
  281. 273.
    Mountain A, Adair JR: Engineering antibodies for therapy. Biotechnol Genet Eng Rev 1992; 10: 1–142.PubMedGoogle Scholar
  282. 274.
    Mujoo K, Kipps TJ, Yang HM et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989; 49: 2857–61.PubMedGoogle Scholar
  283. 275.
    Mulshine JL, Avis I, Treston AM et al. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann NYAcad Sci 1988; 547: 360–72.Google Scholar
  284. 276.
    Munn DH, Cheung N-KV. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987; 47: 6600–5.PubMedGoogle Scholar
  285. 277.
    Murray JL, Rosenblum MG, Sobol RE et al. Radioimmunoimaging in malignant melanoma with 111-In-labeled monoclonal antibody 96.5. Cancer Res 1985; 45: 2376–81.PubMedGoogle Scholar
  286. 278.
    Murray JL, Rosenblum MG, Lamki K et al. Clinical parameters related to optimal tumor locali%ation of indium-111-labeled mouse antimelanoma monoclonal antibody ZME018. J Nucl Med 1987; 28: 25–33.PubMedGoogle Scholar
  287. 279.
    Murray JL, Cunningham JE, Brewer H et al. Phase I trial of murine monoclonal antibody 14G21 administered by prolonged intravenous infusion in patients with neuroectodermal tumor. J Clin Oncol 1994; 12: 184–93.PubMedGoogle Scholar
  288. 280.
    Nabholt% JM, Crown J, Yonemoto I et al. Results of two open label multicentre pilot phase II trials of Herceptin in combination with docetaxel and platinum salts (cis-or carboplatin) as therapy for advanced breast cancer in women overexpressing HER2. Breast Cancer Res Treat 2000; 64 (abstact 327).Google Scholar
  289. 281.
    Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40: 3147–54.PubMedGoogle Scholar
  290. 282.
    Nayak SK, Schilt% PM, Dillman RO. Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human y-interferon gene versus incubation with soluble y-interferon. J Interferon Cytokine Res 1999; 19: 49–58.PubMedGoogle Scholar
  291. 283.
    Nicholson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 1987; 47: 1473–87.Google Scholar
  292. 284.
    Nishihara T, Sawada T, Yamamoto A et al. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer. Jpn J Cancer Res 2000; 91: 817–24.PubMedGoogle Scholar
  293. 285.
    Nisonoff A. Idiotypes: concepts and applications. J Immunol 1991; 147: 2429–38.PubMedGoogle Scholar
  294. 286.
    O’Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–70.PubMedGoogle Scholar
  295. 287.
    Oldham RK. Monoclonal antibodies in cancer therapy. J Clin Oncol 1983; 1: 582–90.PubMedGoogle Scholar
  296. 288.
    Oldham RK. Biologicals and biological response modifiers: the fourth modality of cancer treatment. Cancer Treat Rep 1984; 68: 221–32.PubMedGoogle Scholar
  297. 289.
    Oldham RK, Foon KA, Morgan C et al. Monoclonal antibody therapy of malignant melanoma: in vivo locali%ation in cutaneous metastases after intravenous administration. J Clin Oncol 1984; 2: 1235–44.PubMedGoogle Scholar
  298. 290.
    Oldham RK. Monoclonal antibodies: does sufficient selectivity to cancer cells exist for therapeutic application? J Biol Response Med 1987; 6: 227–34.Google Scholar
  299. 291.
    Osterborg A, Dyer MJS, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously un-Google Scholar
  300. treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–74.Google Scholar
  301. 292.
    Oosterwijk E, Debruyne FMJ, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995; 22: 34–41.PubMedGoogle Scholar
  302. 293.
    Overholser JP, Preewett MC, Hooper AT et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89: 74–82.PubMedGoogle Scholar
  303. 294.
    O%aki S, Kosaka M, Wakahara Y et al. Humani%ed antiHM1.24 antibody mediates myeloma cell cytoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999; 93: 3922–30.Google Scholar
  304. 295.
    Pai LH, Bookman MA, O%ols RF et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OBV3-PE in patients with ovarian cancer. J Clin Oncol 1991; 9: 2095–103.PubMedGoogle Scholar
  305. 296.
    Pauletti G, Dandekar S, Rong HM et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridi%ation and immunohistochemistry. J Clin Oncol 2000; 18: 3651–64.PubMedGoogle Scholar
  306. 297.
    Pawson R, Dyer JMS, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667–72.PubMedGoogle Scholar
  307. 298.
    Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humani%ed anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–71.PubMedGoogle Scholar
  308. 299.
    Pere%-Soler R, Donato JN, Shin DM et al. Tumor epidermal growth factor receptor studies in patients with non-smallcell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994; 12: 730–9.Google Scholar
  309. 300.
    Piro LD, White CA, Grillo-Lope% AJ et al. Extended rituximab anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999; 10: 655–61.PubMedGoogle Scholar
  310. 301.
    Prehn RT. Tumor-specific antigens as altered growth factor receptors. Cancer Res 1989; 49: 2823–6.PubMedGoogle Scholar
  311. 302.
    Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 [anti-CD-20] serotherapy of human B cell lymphomas. Blood 1987; 69: 584–91.PubMedGoogle Scholar
  312. 303.
    Presta LG, Chen H, O’Connor SJ et al. Humani%ation of an anti-vascular endotherlial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–9.PubMedGoogle Scholar
  313. 304.
    Prewett M, Rockwell P, Rockwell RF et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 419–27.PubMedGoogle Scholar
  314. 305.
    Prewett M, Rolthman M, Walsal H et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4: 2957–66.PubMedGoogle Scholar
  315. 306.
    Pr%epiorka D, Kernan NA, Ippoliti C et al. Dacli%umab, a humani%ed anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-vs-host disease. Blood 2000; 95: 83–9.Google Scholar
  316. 307.
    Pukel CS, Lloyd KO, Travassos LR et al. GD3, a prominent ganglioside of human melanoma. J Exp Med 1982; 155: 1133–47.PubMedGoogle Scholar
  317. 308.
    Punt CJ, Nacy A, Douillard J et al. Edrecolomab (17-A antibody) alone or in combination with 5-fluorouracil-based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc Am Soc Clin Oncol 2001; 20: 123a (abstract 487).Google Scholar
  318. 309.
    Ragnhammar P, Pagerberg J, Frodin JE et al. Effect of monoclonal antibody 17–1A and GM-CSF in patients with advanced colorectal carcinoma: long-lasting complete remissions can be induced. Int J Cancer 1993; 53: 751–8.PubMedGoogle Scholar
  319. 310.
    Rai K, Mercier RJ, Cooper MR et al. Campath-1H is an effective salvage therapy for fludarabine failing CLL patients: results of a phase II trial. Blood 2000; 96: 163a (abstract 703).Google Scholar
  320. 311.
    Rankin EM, Hekman A, Somers R et al. Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood 1985; 65: 1373–81.PubMedGoogle Scholar
  321. 312.
    Reichardt VL, Okada CY, Stockerl-Goldstein KE et al. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 1997; 3: 157–63.PubMedGoogle Scholar
  322. 313.
    Rewald U, Engert A, Diehl V. Monoclonal antibody antiCD20 antibody Rituximab (Rituxan) for treatment of CD2- positiveHodgkin’s lymphoma: the German experience. Blood 2000; 96: 729a (abstract 3153).Google Scholar
  323. 314.
    Richards JM, Vogel%ang NJ, Bluestone JA. Neurotoxicity after treatment with muromonab-CD3. N Engl J Med 1990; 323: 487–8.PubMedGoogle Scholar
  324. 315.
    Rietmuller G, Schneider-Gadicke E, Schlimok G et al. Randomi%ed trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343: 1177–83.Google Scholar
  325. 316.
    Riethmuller G, Hol% E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomi%ed trial J Clin Oncol 1998; 16: 1788–94.Google Scholar
  326. 317.
    Rit% J, Pesando JM, Notis-McConarty J et al. Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol 1980; 125: 1506–14.Google Scholar
  327. 318.
    Rit% J, Pesando JM, Sallan SE et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 1981; 58: 141–52.Google Scholar
  328. 319.
    Robert F, E%ekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234–43.PubMedGoogle Scholar
  329. 320.
    Romaguera JE, Dang NH, Hagemeister FB et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma. Blood 2000; 96: 733a (abstract 3170).Google Scholar
  330. 321.
    Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 25: 323–88.PubMedGoogle Scholar
  331. 322.
    Rubin SC. Monoclonal antibodies in the management of ovarian cancer: a clinical perspective. Cancer 1993; 71: 1602–12.PubMedGoogle Scholar
  332. 323.
    Rudders RA, Levin A, Jespersen D et al. Crossreacting human lymphoma idiotypes. Blood 1992; 80: 1039–44.PubMedGoogle Scholar
  333. 324.
    Ryan KP, Dillman RO, DeNardo SJ et al. Breast cancer imaging with In-111 human IgM monoclonal antibodies. Radiology 1988; 167: 71–5.PubMedGoogle Scholar
  334. 325.
    Rydh A, Riklund-Ahlstrom K, Widmark A et al. Radioimmunotherapy of DU-145 tumours in nude mice–a pilot study with E-4, a novel monoclonal antibody against prostate cancer. Acta Oncol 1999; 38: 1075–9.PubMedGoogle Scholar
  335. 326.
    Saleh MN, LoBuglio AF, Wheeler RH et al. A phase II trial of murine monoclonal antibody 17–1A and interferon-gamma: clinical and immunological data. Cancer Immunol 1990; 32: 185–90.Google Scholar
  336. 327.
    Saleh MN, Kha%aeli MB, Wheeler RH et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992; 52: 4342–7.PubMedGoogle Scholar
  337. 328.
    Saleh MN, Kha%aeli MD, Wheeler RH et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 inGoogle Scholar
  338. patients with malignant melanoma. Hum Antibod Hybrid 1992: 3: 19–23.Google Scholar
  339. 329.
    Saleh MN, Kha%aeli MB, Gri%%le WE et al. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res 1993; 53: 4555–62.PubMedGoogle Scholar
  340. 330.
    Saleh MN, LeMaistre CF, Ku%el TM et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998; 39: 63–73.PubMedGoogle Scholar
  341. 331.
    Schecter AL, Stern DF, Vaidanathan L et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumor antigen. Nature 1984; 312: 513–16.Google Scholar
  342. 332.
    Scheinberg DA, Lovett D, Divgi CR et al. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internali%ation of radionuclide. J Clin Oncol 1991; 9: 478–90.PubMedGoogle Scholar
  343. 333.
    Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by antiVEGF neutrali%ing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metast Rev 1999; 18: 473–81.Google Scholar
  344. 334.
    Schlom J, Wunderlich D, Teramoto YA. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci USA 1980; 77: 6841–5.PubMedGoogle Scholar
  345. 335.
    Schneck D, Butler F, Dugan W et al.. Phase I studies with a murine monoclonal antibody vinca conjugate (KS1/4- DAVLB) in patients with adenocarcinoma antibody. Immunoconj Radiopharm 1989; 2: 93–100.Google Scholar
  346. 336.
    Schnipper LE. Clinical implications of tumor cell heterogeneity. N Engl J Med 1986; 314: 1423–31.PubMedGoogle Scholar
  347. 337.
    Schoof DD, Selleck CM, Massaro AF et al. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 1990; 50: 1138–43.PubMedGoogle Scholar
  348. 338.
    Schroff RW, Farrell MM, Klein RA et al. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol 1984; 133: 1641–8.PubMedGoogle Scholar
  349. 339.
    Schroff RW, Foon KA, Wilburn SB et al. Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879–85.PubMedGoogle Scholar
  350. 340.
    Sears HF, Atkinson B, Mattis J et al. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1982; 1: 762–5.PubMedGoogle Scholar
  351. 341.
    Sears HF, Herlyn D, Steplewski Z et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Modif 1984; 3: 136–50.Google Scholar
  352. 342.
    Sears HF, Herlyn D, Steplewski Z et al. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45: 5910–13.PubMedGoogle Scholar
  353. 343.
    Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastu%umab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587–95.PubMedGoogle Scholar
  354. 344.
    Shakib F, ed. Basic and Clinical Aspects of IgG Subclasses. New York: Karger, 1986.Google Scholar
  355. 345.
    Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 68: 673–83.Google Scholar
  356. 346.
    Shaw DR, Kha%aeli MB, LoBuglio AF. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst 1988; 80: 1553–9.PubMedGoogle Scholar
  357. 347.
    Shawler DL, Miceli MC, Wormsley SB et al. Induction of in vitro and in vivo antigenic modulation by the anti-human T cell monoclonal antibody T101. Cancer Res 1984; 44: 5921–7.PubMedGoogle Scholar
  358. 348.
    Shawler DL, Bartholomew RM, Smith LM et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530–5.PubMedGoogle Scholar
  359. 349.
    Shawler DL, Wormsley SB, Dillman RO et al. The use of monoclonal antibodies and flow cytometry to detect peripheral blood and bone marrow involvement of a diffuse, poorly differentiated lymphoma. Int J Immunopharmacol 1985; 7: 423–32.PubMedGoogle Scholar
  360. 350.
    Shawler DL, McCallister TJ, Sobol RE et al. Serologic and cellular assays to monitor therapy with murine monoclonal antibodies. J Clin Lab Anal 1987; 2: 184–90.Google Scholar
  361. 351.
    Shen JW, Atkinson B, Koprowsky H et al. Binding of murine immunoglobulin to human tissues after immunotherapy with anti-colorectal carcinoma monoclonal antibody. Int J Cancer 1984; 33: 465–8.PubMedGoogle Scholar
  362. 352.
    Shin DM, Donato NJ, Pere%-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7: 1204–13.PubMedGoogle Scholar
  363. 353.
    Sikora K, Wright R. Human monoclonal antibodies to lung cancer antigens. Br J Cancer 1981; 43: 696–700.PubMedPubMedCentralGoogle Scholar
  364. 354.
    Sikora K, Alderson T, Phillips J et al. Human hybridomas from malignant gliomas. Lancet 1982; 1: 11–14.PubMedGoogle Scholar
  365. 355.
    Sikora K, Alderson T, Ellis J et al. Human hybridomas from patients with malignant disease. Br J Cancer 1983; 47: 135–45.PubMedPubMedCentralGoogle Scholar
  366. 356.
    Sikora K. Human monoclonal antibodies. Br Med Bull 1984; 40: 209–12.PubMedGoogle Scholar
  367. 357.
    Sikorska HM. Therapeutic applications of antiidiotype antibodies. J Biol Respons Modif 1988; 7: 327–58.Google Scholar
  368. 358.
    Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2–2/neu oncogene. Science 1987; 235: 177–82.PubMedGoogle Scholar
  369. 359.
    Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92.PubMedGoogle Scholar
  370. 360.
    Sliwkowski MX, Lofgren JA, Lewis GC et al. Nonclinical studies addressing the mechanism of action of trastu%umab (Herceptin). Semin Oncol 1999; 26 (Suppl. 12): 60–70.PubMedGoogle Scholar
  371. 361.
    Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xeno-grafts in nude mice. Prostate 2001; 48: 47–53.PubMedGoogle Scholar
  372. 362.
    Smith-Jones PM, Vallabhajosula S, Goldsmith SJ et al. In vitro characteri%ation of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000; 60: 5237–43.PubMedGoogle Scholar
  373. 363.
    Sobol RE, Dillman RO, Smith JD et al. Phase I evaluation of murine monoclonal anti-melanoma antibody in man: preliminary observations. In: Mitchell MS, Oettgen HF, eds. Hybridomas in Cancer Diagnosis and Treatment. New York: Raven Press, 1981; 21: 199–206.Google Scholar
  374. 364.
    Sodee DB, Malguria N, Faulhaber P et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000; 56: 988–93.PubMedGoogle Scholar
  375. 365.
    Soh EY, Eigelberger MS, Kim KJ et al. Neutrali%ing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000; 128: 1059–1065.PubMedGoogle Scholar
  376. 366.
    Soiffer RJ, Chapman PB, Murray C et al. Administration of R24 monoclonal antibody and low-dose interleukin-2 for malignant melanoma. Clin Cancer Res 1997; 3: 17–24.PubMedGoogle Scholar
  377. 367.
    Sosman JA, Weiss GR, Margolin KA et al. Phase IB clinical trial of anti-CD3 followed by high dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma; clinical and immunologic effects. J Clin Oncol 1993; 11: 1496–505.PubMedGoogle Scholar
  378. 368.
    Steffens MG, Boerman OC, Oosterwisk-Wakka JC et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529–37.PubMedGoogle Scholar
  379. 369.
    Starling J, Cote RJ, Marder P et al. Tissue distribution and cellular location of the antigens recogni%ed by human monoclonal antibodies 16.88 and 28A32. Cancer Res 1988; 48: 7273–8.PubMedGoogle Scholar
  380. 370.
    Stein H, Hummel H. Cellular origin and clonality of classic Hodgkin’s lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999; 36: 233–41.PubMedGoogle Scholar
  381. 371.
    Steplewski Z, Sun LK, Shearman CW et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 1988; 85: 4852–6.PubMedGoogle Scholar
  382. 372.
    Stevenson FK, Bell AJ, Cusack R et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991; 77: 1071–9.PubMedGoogle Scholar
  383. 373.
    Stevenson FK, Wrightham M, Glennie MJ et al. Antibodies to shared idiotypes as agents for analysis and therapy for human B cell tumors. Blood 1986; 68: 430–6.PubMedGoogle Scholar
  384. 374.
    Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960; 13: 79–81.PubMedGoogle Scholar
  385. 375.
    Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphas Tumor Immunol 1996; 19: 184–98.Google Scholar
  386. 376.
    Swisher EM, Shawler DL, Collins HA et al. Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 1991; 77: 1977–82.PubMedGoogle Scholar
  387. 377.
    Talwar GP, Gupta R, Gupta SK et al. A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells. Prostate 2001; 46: 207–13.PubMedGoogle Scholar
  388. 378.
    Tang SC, Hewitt K, Reis MD, Berinstein NL. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 1996; 24: 93–101.PubMedGoogle Scholar
  389. 379.
    Tempero MA, Sivinski C, Steplewski Z et al. Phase II trial of interferon gamma and monoclonal antibody 17–1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol 1990; 8: 2019–26.PubMedGoogle Scholar
  390. 380.
    Thomas DA, O’Brien S, Cortex J et al. Pilot study of rituximab in refractory or relapsed hairy cell leukemia. Blood 1999; 94: 705a (abstract 3116).Google Scholar
  391. 381.
    Thompson CH, Stacker SA, Salehi N et al. Immunoscintigraphy for detection of lymph node metastases from breast cancer. Lancet 1984; 2: 1245–1247.PubMedGoogle Scholar
  392. 382.
    Thurin J, Thurin M, Kimoto Y et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 1987; 47: 1229–33.PubMedGoogle Scholar
  393. 383.
    Tibben JG, Boerman OC, Massuger LF et al. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/ TR F(ab~)2 in ovarian carcinoma patients. Int J Cancer 1996; 66: 477–83.PubMedGoogle Scholar
  394. 384.
    Treon SP, Belch AR, Grossbard ML et al. Phase II study of single agent rituximab in previously treated multiple myeloma patients; patients with CD20+ BM plasma cells may derive benefit from rituximab. Blood 2000; 96: 164a (abstract 704).Google Scholar
  395. 385.
    Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27 (Suppl. 12): 79–85.PubMedGoogle Scholar
  396. 386.
    Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 1981; 294: 171–3.PubMedGoogle Scholar
  397. 387.
    Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for Trastu%umab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714–21.PubMedGoogle Scholar
  398. 388.
    Urba WJ, Ewel C, Kopp W et al. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. Cancer Res 1992; 52: 2394–401.PubMedGoogle Scholar
  399. 389.
    Vadhan-Raj S, Cordon-Cardo C, Carswell E et al. Phase I trial of mouse monoclonal antibody against GD3 ganglio-side in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636–48PubMedGoogle Scholar
  400. 390.
    Valone FH, Kaufman PA, Guyre PM et al. Phase I1 /Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13: 2281–92.PubMedGoogle Scholar
  401. 391.
    Van Kijk J, Warnaar SO, van Eendenburg JD et al. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recogni%ing renal-cell carcinoma and CD3 antigen. Int J Cancer 1989; 43: 344–9.Google Scholar
  402. 392.
    Van Zaanen HC, Lokhorst HM, Aarden LA et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998; 102: 783–90.PubMedGoogle Scholar
  403. 393.
    Viloria–Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor–blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61–5090–101.Google Scholar
  404. 394.
    Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 1994; 54: 5301–9PubMedGoogle Scholar
  405. 395.
    Vogel C, Cobleigh MA, Tripathy D et al. First-liune, single-agent Herceptin (trastu%umab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001; 37(Suppl. 1): S25- S29.Google Scholar
  406. 396.
    Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001; 19: 389–97PubMedGoogle Scholar
  407. 397.
    Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232: 727–32.PubMedGoogle Scholar
  408. 398.
    Waldmann, TA, Goldman CK, Bongiovanni KF et al. Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805–16.PubMedGoogle Scholar
  409. 399.
    Waldmann TA, White JD, Goldman CK et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993; 82: 1701–12.PubMedGoogle Scholar
  410. 400.
    Wallach D, Fellous M, Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982; 299: 833–5.PubMedGoogle Scholar
  411. 401.
    Walport MJ. Complement. N Engl J Med 1991; 344: 1058–66, 1140–4.Google Scholar
  412. 402.
    Watanabe M, Wallace PK, Keler T et al. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res 1999; 53: 199–207.Google Scholar
  413. 403.
    Webb DS, Gerrard TL. IFN-a and IFN-y affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J Immunol 1990; 144: 3643–8.PubMedGoogle Scholar
  414. 404.
    Weber DM, Gavino M, Huh Y et al. Phenotypic and clinical evidence supports rituximab for Waldenstrom’s macroglobulinemia. Blood 1999; 94 (Suppl. 1): 125a (abstract 551).Google Scholar
  415. 405.
    Weiner LM, Moldofsky PH, Gatenby RA et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17–1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568–73.PubMedGoogle Scholar
  416. 406.
    Weiner LM, Steplewski Z, Koprowski H et al. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Res 1988; 48: 1042–6.PubMedGoogle Scholar
  417. 407.
    Weiner LM, Hillstrom JR. Bispecific anti-idiotype/antiCD3 antibody therapy of murine B cell lymphoma. J Immunol 1991; 147: 4035–44.PubMedGoogle Scholar
  418. 408.
    Weiner LM, Harvey E, Padavic-Shaller K et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17–1A therapy in pancreatic carcinoma. J Immun-other 1993; 13: 110–16.Google Scholar
  419. 409.
    Weiner LM. Bispecific antibodies in cancer therapy. Cancer J 2000; (Suppl. 3 ): S265–S269.Google Scholar
  420. 410.
    Welte K, Miller G, Chapman PB et al. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 1987; 139: 1763–71.PubMedGoogle Scholar
  421. 411.
    Wettendorff M, Hiopoulos D, Tempero M et al. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17–1A. Proc Natl Acad Sci USA 1989; 86: 3787–91.PubMedGoogle Scholar
  422. 412.
    White CA. Rituximab immunotherapy for non-Hodgkin’s lymphoma. Cancer Biother Radiopharm. 1999; 14: 241–50.PubMedGoogle Scholar
  423. 413.
    Wilkinson I, Jackson C-JC, Lang GM et al. Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol: transfer of tolerance by T cells and by T cell extracts. J Immunol 1987; 139: 326–31.PubMedGoogle Scholar
  424. 414.
    Winkler U, Jensen M, Man%ke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–24.PubMedGoogle Scholar
  425. 415.
    Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293–9.PubMedGoogle Scholar
  426. 416.
    Wiseman C, Hammock V, Barton L et al. Clinical responses of primary human CNS tumors to OKT3/cyclophosphamide. J Immunother 1994; 16: 245.Google Scholar
  427. 417.
    Wong KK, Sweet DL, Variakoujis D. The treatment of lymphoblastic lymphoma with antithymocyte globulin. Cancer 1981; 50: 57–61.Google Scholar
  428. 418.
    Wong JF, Colvin RB. Bi-specific monoclonal antibodies. Selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139: 1369–74.PubMedGoogle Scholar
  429. 419.
    Woodhouse CS, Morgan AC Jr. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characteri%ation of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Cancer Res 1989; 49: 2766–72.PubMedGoogle Scholar
  430. 420.
    Wright PW, Hellstrom KE, Hellstrom IE et al. Serotherapy of malignant disease. Med Clin N Am 1976; 60: 607–22.PubMedGoogle Scholar
  431. 421.
    Wurflein D, Dechant M, Stockmeyer B et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 1998; 58: 3051–8.PubMedGoogle Scholar
  432. 422.
    Yang H, Rosove HM, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62: 247–50.PubMedGoogle Scholar
  433. 423.
    Ye D, Mendelsohn J, Fan Z. Augmentation of a humani%ed anti-Her2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731–8.PubMedGoogle Scholar
  434. 424.
    Yoshikawa K, Ueda R, Obata Y et al. Human monoclonal antibody reactive to stomach cancer produced by mouse-human hybridoma technique. Jpn J Cancer Res 1986; 77: 1122–33.PubMedGoogle Scholar
  435. 425.
    Yu AL, Martina M, Uttenreuther-Fischer MM et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16: 2169–80.PubMedGoogle Scholar
  436. 426.
    Yuon S, Zhang H, Chen Q. Generation and application of monoclonal antibody to human pancreatic cancer. Hybridoma 1996; 15: 289–93.Google Scholar
  437. 427.
    Ziegler LD, Pala%%olo, Cunningham J et al. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 1992; 10: 1470–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Robert O. Dillman

There are no affiliations available

Personalised recommendations